CAMBRIDGE, Mass., Feb. 23 /PRNewswire/ -- ETEX Corporation, an advanced biomaterials company, announced today that it has received the European Union (EU) CE Mark (Conformite Europeene) for both Beta-bsm(TM) Injectable Paste and Gamma-bsm(TM) Moldable Putty.
Beta-bsm(TM) and Gamma-bsm(TM) are next generation bone substitute materials based on ETEX’s proprietary nanocrystalline calcium phosphate technology. This hard-setting nanocrystalline technology provides the optimal osteoconductive scaffold for new bone growth that is remodeled into bone over time. Offered in an injectable paste or moldable putty format, Beta-bsm(TM) and Gamma-bsm(TM) provide the surgeon the flexibility to adapt to specific patient needs.
Brian Ennis, CEO of ETEX Corporation, states “We are excited to continue the global expansion and distribution of our nanocrystalline calcium phosphate platform, now offering European surgeons bone graft substitutes with enhanced performance including faster setting times, higher compressive strength, and user friendly mixing and delivery systems. Our European distribution network is rapidly expanding with initiatives in all major markets.”
About ETEX Corporation
Established in 1989, ETEX Corporation develops, manufactures and commercializes calcium phosphate-based biomaterials for improved orthopedic clinical outcomes. A leader in bioresorbable bone substitute materials, ETEX focuses on expanding applications through combinations with cells, biologics, or therapeutic agents delivered in minimally invasive and easy to use systems. For more information, visit www.etexcorp.com.
